Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symptomatic adverse events (AEs) in cancer treatment trials. However, there are currently no standard recommended approaches for integrating patient-reported AE measures into trials. Methods Approaches are identified from prior trials for selecting AEs for solicited patient-reporting; administering patient-reported AE measures; and analyzing and reporting results. Findings Approaches for integrating patient-reported AE measures into cancer trials generally combine current standard methods for clinician-reported AEs as well as established best practices for employing PRO measures. Specific AEs can be selected for a PRO questionnaire based on common and expected reactions in a given trial context, derived from literature review and qualitative/mixed methods evaluations and should be the same set administered across all arms of a trial. A mechanism for collecting unsolicited patient-reported AEs will also ideally be included. Patients will preferably report at baseline and end of active treatment as well as on a frequent standardized schedule during active treatment, such as weekly from home, with a recall period corresponding to the frequency of reporting (e.g., past 7 days). Less frequent reporting may be considered after an initial intensive monitoring period for trials of prolonged treatments and during long-term follow up. Electronic PRO data collection is preferred. Backup data collection for missed PRO reports is advisable to boost response rates. Analysis can employ a combination of approaches to AE and PRO data. If a high proportion of patients is experiencing baseline symptoms, systematic subtraction of these from on-study AEs should be considered to improve reporting of symptoms related to treatment. More granular longitudinal analyses of individual symptoms can also be useful. Implications Methods are evolving for integrating patient-reported symptomatic AEs into cancer trials. These methods are expected to further evolve as more data from trials become available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0830 · Cited by 2,593
Self-citationDueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030
Self-citationBasch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653
Self-citationThe Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646
Self-citationGwaltney, C. J., Shields, A. L., & Shiffman, S. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00231.x · Cited by 623
Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9334 · Cited by 497
Cited by
Sorafenib for Advanced and Refractory Desmoid Tumors
Gounder, M. M., Mahoney, M. R., Van Tine, B. A., Ravi, V., Attia, S., Deshpande, H. A., Gupta, A. A., Milhem, M. M., Conry, R. M., Movva, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805052 · Cited by 463
Self-citationvan der Wouden, C., Cambon‐Thomsen, A., Cecchin, E., Cheung, K., Dávila‐Fajardo, C., Deneer, V., Dolžan, V, Ingelman‐Sundberg, M., Jönsson, S., Karlsson, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.602 · Cited by 306
Bevans, M., El-Jawahri, A., Tierney, D. K., Wiener, L., Wood, W. A., Hoodin, F., Kent, E. E., Jacobsen, P. B., Lee, S. J., Hsieh, M. M., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2016.09.011 · Cited by 166
Morishita, D., Tomita, T., Mori, S., Kimura, T., Oshima, T., Fukui, H., & Miwa, H. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000942 · Cited by 65
Cho, Y., Zhang, H., Harris, M. R., Gong, Y., Smith, E. L., & Jiang, Y. (2021) · Journal of Medical Internet Research · doi:10.2196/24638 · Cited by 53
“There is growing evidence for the use of electronic technology systems to collect patient-reported symptoms [5].”
BackgroundMethod
Metadata
- Authors
- Basch, E., Rogak, L. J., & Dueck, A. C.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 38
- Issue
- 4
- Pages
- 821-830
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2314226163
- Cited by
- 101
- References
- 6
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. https://app.cochat.ai/papers/10.1016/j.clinthera.2016.03.011
- The paper
- Basch, E., Rogak, L. J., & Dueck, A. C. (2016). Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2016.03.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.